The existing three-year collaboration between Karo Bio of Sweden andBristol-Myers Squibb of the USA concerning the development of new drugs for metabolic disorders has been extended for a second time, and expanded to include Karo Bio's Molecular Braille technology.
Originally signed in 1997, the collaboration centers on using the thyroid hormone receptor as a drug target in developing new treatments for metabolic disorders, and has already resulted in two clinical development candidates in the area of obesity. A one-year extension was agreed last October to develop second-generation compounds, and the latest modification to the deal will allow B-MS to apply the Molecular Braille technology, which makes it possible to quickly link the action of a substance on a nuclear receptor to tissue-selective biological activities. This is the first time, that Karo Bio has licensed out the latter platform, which it acquired along with US firm Novalon last year (Marketletter May 15, 2000).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze